Company Overview and News

 
3 Big Pharma Stocks with Huge Future Growth Potential

14h investorplace
You might not be aware of it, but big pharma stocks have gone through a difficult period for many years. A lot of the big drugs at the big pharma stocks went off patent, and the revenue for some of the big pharma stocks has fallen off as a result.

 
BYD wins contract to build Brazil monorail, landing Buffett-backed firm its biggest overseas deal

15h scmp
BYD won its biggest overseas order for monorail systems in an affirmation of efforts by the Chinese electric-vehicle maker to revive profit growth.

 
In Full Flow: Pipeline Additive Sales Boom Amid Oil Bottlenecks

15h rigzone
HOUSTON/CALGARY, Alberta, May 24 (Reuters) - Pipeline bottlenecks have vexed North American oil producers this year, but for companies making a little-known additive called drag-reducing agent (DRA), they have provided a veritable windfall.

 
Should Value Investors Take A Road Trip With RV Makers?

2018-05-23 seekingalpha
Comparison of two of the leading companies in the industry and review the characteristics needed for an evaluation of a company's value.

 
Should SPDR Portfolio S&P 500 Value ETF (SPYV) Be on Your Investing Radar?

2018-05-23 zacks
Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the SPDR Portfolio S&P 500 Value ETF (SPYV - Free Report) is a passively managed exchange traded fund launched on 09/25/2000.

 
Should Have STORE Capital Turned Down Buffett's Investment?

2018-05-23 seekingalpha
STORE Capital issued 18.6 million shares to Berkshire Hathaway at 5.73% yield, its highest issuance yield in history.

 
Sun, sea, sand … and Warren Buffett? China’s tropical Hainan wants the big names to come and invest

2018-05-23 scmp
After Beijing says it will turn the island into a huge free-trade zone, the local government publishes a list of the world’s biggest business names it wants to talk to about setting up shop there

 
Warren Buffett Loves TEVA Stock and You Should Too

2018-05-23 investorplace
While Teva Pharmaceutical Industries Ltd (ADR) ADR (NYSE:TEVA) faded from last Wednesday highs, shares ultimately climbed about 3% that day. No, it wasn’t earnings or a new drug that gave TEVA stock a bump. Instead, it was Warren Buffett.

 
Antares Pharma, Excellent Risk-Reward Profile

2018-05-22 seekingalpha
Company remains a viable acquisition candidate, especially in the likely aftermath of Xyosted being approved by the FDA.

 
TMF: OT: Markel Brunch Notes / Berkshire Hathaway

2018-05-22 boards.fool
Folders | Best Of | Favorites & Replies | Settings | Start a New Board | My Fool | Help |

1
Digital Power Corporation's (DPW) CEO Milton Todd Ault III on Q1 2018 Results - Earnings Call Transcript

2018-05-22 seekingalpha
Welcome everybody. We are about to begin the webinar first quarter 2018 financial review. Before we do so we will start with the Safe Harbor Statement and then I will turn the meeting over to Mr. Milton Todd Ault III, CEO and Chairman of the Board of DPW Holdings as well as Will Horne, CFO of DPW Holdings.

 
China Finance Online Co.'s (JRJC) CEO Zhiwei Zhao on Q1 2018 Results - Earnings Call Transcript

2018-05-22 seekingalpha
China Finance Online Co. Limited. (NASDAQ:JRJC) Q1 2018 Results Earnings Conference Call May 21, 2018 8:00 PM ET

 
Monday Apple Rumors: Beats Line May Get Its Own HomePod

2018-05-21 investorplace
Leading the Apple Inc. (NASDAQ:AAPL) rumor mill today is news of a cheaper HomePod on the way. Today, we’ll look at that and other Apple Rumors for Monday.

 
Manning & Napier Is A Value Mirage

2018-05-21 seekingalpha
When taking into account its complicated capital structure, the valuation for MN stock is lower than its current price.

 
Phillips 66 Is Cashing In On The Oil Spread

2018-05-21 seekingalpha
The refining company can take advantage of the $8 differential between West Texas Intermediate crude oil and Brent crude.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

17h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 084670108